Showing posts with label pegylated liposomal doxorubicin. Show all posts
Showing posts with label pegylated liposomal doxorubicin. Show all posts

Thursday, February 9, 2012

Upper gastrointestinal bleeding due to gastric and duodenal Kaposi´s sarcoma

Upper gastrointestinal bleeding due to gastric and duodenal Kaposi´s sarcoma.


Feb 2012


CASE REPORT

A 30-year-old homosexual male was recently diagnosed with HIV infection (category A2). He was been admitted into the hospital because of anal pain and diarrhea of 8 months. He presented purplish cutaneous lesions, laterocervical adenopathies and a palpable anal mass. The rest of physical exploration did not reveal any other significant alteration. The amount of CD4 was 350 cells/mL and the viral load of 10,000 copies/mL. Fecal cultures were negative. A colonoscopy was performed and detected an ulcerated rectal mass that was biopsied (Fig. 1). He presented an episode of hematemesis so it was performed an upper endoscopy which demonstrated the presence of lesions suggestive of Kaposi’s in the stomach (Fig. 2) and duodenum (Fig. 3). The definitive anatomopathologic diagnosis of the cutaneous anal lesion, gastric biopsy and adenopathies was Kaposi’s sarcoma. The patient began antiretroviral treatment and
chemotherapy with liposomal doxorubicin and radiotherapy.

DISCUSSION

Kaposi’s sarcoma is a vascular tumor described first in 1872. It is associated with the immunosuppressive state in patients affected by infection with HIV. It usually appears as small purplish cutaneous lesions although it can affect other mucosa, organs and lymphatic system. Postmortem studies suggest the presence of visceral involvement in more than 75% of the
cases, being the lungs and gastrointestinal tract the most common ones. It can affect any part of the digestive tract, from the oropharynx to the rectum. They have been described cases of hepatic, splenic and pancreatic disease (1). Gastrointestinal Kaposi’s sarcoma frequently has a silent clinical course although it can cause abdominal pain, gastrointestinal bleeding and
intestinal obstruction (2). Endoscopically it can presents as a purplish nodule, a polipoid mass or a hemorragic macule (3).

Full Length Article with diagnostic Images:

Tuesday, September 29, 2009

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma.

Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma.


Department of Internal Medicine, School of Medicine, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana.

Correspondence: Francesca Cainelli, Senior Lecturer in Internal Medicine, School of Medicine, Faculty of Health Sciences, University of Botswana, Private Bag 0022, Gaborone, Botswana, Tel +267.3554563, Email, francescacainelli@yahoo.it

Kaposi's sarcoma is a vascular tumor linked to the presence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) and the incidence of which has increased considerably the world over after the onset of the human immunodeficiency virus (HIV) pandemic. Antiretroviral therapy combined with cytotoxic agents has been established as the treatment of choice in the past 10 years. Among chemotherapeutic agents, pegylated liposomal doxorubicin has become the preferred one for patients with HIV-associated Kaposi's sarcoma in Western countries. The drug in this formulation localizes better to the tumor and has higher efficacy. Skin toxicity, mucositis, and leukopenia/neutropenia are the main side effects. Hepatotoxicity and mild cardiotoxicity are observed less frequently. Pegylated liposomal doxorubicin impacts favorably on quality of life. Although cost effective in Western countries, the drug is less so in developing countries.

Full Text Article:

PubMedCentral/Fovepress